The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC).
 
Yasir Y Elamin
Consulting or Advisory Role - AstraZeneca; Lilly; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly
 
Marcelo Vailati Negrao
Consulting or Advisory Role - Merck; Mirati Therapeutics
Research Funding - Alaunos Therapeutics; AstraZeneca; Checkmate Pharmaceuticals; Genentech; Mirati Therapeutics; Novartis; Pfizer; ZIOPHARM Oncology
Other Relationship - Apothecom; Ashfield Healthcare; ZIOPHARM Oncology
 
Frank V. Fossella
No Relationships to Disclose
 
Lauren Averett Byers
Consulting or Advisory Role - Abbvie; Alethia Biotherapeutics; AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Genentech; Genmab; Jazz Pharmaceuticals; Merck; Pfizer; PharmaMar; Sierra Oncology; Tolero Pharmaceuticals
Research Funding - AstraZeneca (Inst); Genmab (Inst); Sierra Oncology; Tolero Pharmaceuticals
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Geneplus; innovent biologics; Innovent Biologics; Innovent Biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Capital Medical University; Geneplus; Johnson & Johnson/Janssen; Novartis
Research Funding - Merck; Novartis
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital
 
Carl Michael Gay
No Relationships to Disclose
 
Janet Chen Tu
No Relationships to Disclose
 
Jenny Vu Pozadzides
No Relationships to Disclose
 
Hai T. Tran
Research Funding - Bayer (Inst); Bristol Myers Squibb (Inst); Guardant Health (Inst); ZIOPHARM Oncology (Inst)
 
Charles Lu
No Relationships to Disclose
 
Lei Feng
No Relationships to Disclose
 
Amy R. Spelman
No Relationships to Disclose
 
George R. Blumenschein
Employment - Janssen (I); johnon & Johnson (I)
Stock and Other Ownership Interests - Virogin Biotech
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo, INC; Genentech; Gilead Sciences; Instil Bio; Janssen Oncology; Johnson & Johnson (I); Lilly; Maverick Therapeutics; MedImmune; Merck; Novartis; Novartis; Roche; Tyme; Virogin Biotech; Xcovery
Research Funding - Adaptimmune; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Daiichi Sankyo INC; Exelixis; Genentech; GlaxoSmithKline; Immatics; Immunocore; Incyte; Kite, a Gilead company; Macrogenics; MedImmune; Merck; Novartis; Regeneron; Repertoire Immune Medicines; Roche; Tmunity Therapeutics, Inc.; Torque; Verastem; Xcovery
 
Anne S. Tsao
Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Lilly; Novartis; Takeda
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Merck; Millennium; Polaris; Seagen; Seagen; Takeda
Patents, Royalties, Other Intellectual Property - UptoDate
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; BrightPath Biotheraputics; Bristol-Myers Squibb; Catalyst Biotech; EMD Serono; Foundation medicine; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Janssen; Kairos Ventures; Leads Biolabs; Lilly; Mirati Therapeutics; Nexus Health Systems; Novartis; Pneuma Respiratory; Roche; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Research Funding - AstraZeneca (Inst); GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations